Compare Ford Motor Company (F) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs BIO-TECHNE Corp — how do they compare? Ford Motor Company trades at $12.28 (market cap $48.33B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Ford Motor Company is far larger — about 4.3× BIO-TECHNE Corp's market cap, and Ford Motor Company pays the higher dividend (4.95%). Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 104 Days and BIO-TECHNE Corp for 63 Days on average.
| F | TECH | |
|---|---|---|
Market Cap | $48.33B | $11.37B |
Volume | 33,572,159 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $72.61 |
52-Week Low | $11.21 | $43.31 |
Typical Hold Time | 104 Days | 63 Days |
Enterprise Value | $180.29B | $11.40B |
Dividend Yield | 4.95% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.25, down 0.2% with bearish technical signals. The company reported mixed quarterly results, beating Q1 and Q2 2026 EPS estimates but missing Q4 2025. Despite $187.3B revenue in 2025, net income was -$8.18B with negative margins. Analyst consensus is mixed with 38% buy ratings and a $15.90 price target. Recent news highlights sales declines and production challenges, though the company maintains strong cash flow from operations.
Ford faces significant headwinds including declining sales, negative profitability, and high debt levels. The stock offers value with low P/E (11.21) and P/S (0.26) ratios, but execution risks and competitive pressures from Asian automakers pose challenges. The dividend provides income support, but investors should weigh fundamental weaknesses against valuation appeal.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
